GlassScriptPhysician profile
Xiang Liu
NPI 1881185718
$2,454.26
in general payments reported to CMS, 2019-2025
21 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.00 · 2021: $30.81 · 2023: $470 · 2024: $707 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $472.61 | 2023-2025 | Livdelzi, Vemlidy |
| Boston Scientific Corporation | $365.69 | 2021-2024 | Spyglass, Dreamtome Rx 49, Axios |
| Janssen Biotech, INC. | $361.44 | 2024-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $256.49 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.35 | 2024-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $133.78 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $86.50 | 2025 | Dupixent |
| Pfizer INC. | $83.89 | 2025 | |
| Intercept Pharmaceuticals, INC. | $69.86 | 2024 | |
| Ardelyx, INC. | $67.11 | 2025 | Ibsrela |
| Lilly USA, LLC | $54.85 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.40 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $43.15 | 2024 | |
| Novo Nordisk INC | $41.95 | 2025 | Wegovy |
| Celgene Corporation | $39.76 | 2024 | Zeposia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $33.12 | 2024 | Cuvrior |
| Qol Medical, LLC | $26.62 | 2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $18.76 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.16 | 2023 | Recorlev |
| Exact Sciences Corporation | $16.77 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiang Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.